for informal feedback under section 587F of the Federal Food, Drug, and Cosmetic Act, as added by section 3, beginning on the effective date of this Act. (e) Previously classified devices Notwithstanding section 587 of the Federal Food, Drug, and Cosmetic Act, as added by section 3, for purposes of subchapter J of chapter V of such Act, as added by section 3, the following apply: (1) In the case of an in vitro clinical test type that has been classified by the Secretary as a class I device pursuant to section 513 of such Act ( 21 U.S.C. 360c ), such in vitro clinical test shall be low-risk, unless the in vitro clinical test is a test described in the second sentence of section 510(l)(1) of such Act or the test is redesignated by the Secretary pursuant to section 587F of such Act. (2) In the case of an in vitro clinical test type that has been classified by the Secretary as a class II device pursuant to section 513 of such Act ( 21 U.S.C. 360c ), such in vitro clinical test shall be moderate-risk, unless inaccurate results from the test would be immediately life threatening or the test is redesignated by the Secretary pursuant to section 587F of such Act. (3) In the case of an in vitro clinical test type that has been classified by the Secretary as a class III device pursuant to section 513 of such Act ( 21 U.S.C. 360c ) or an in vitro clinical test licensed pursuant to section 351 of the Public Health Service Act ( 42 U.S.C. 262 ), such in vitro clinical test shall be high-risk, unless redesignated by the Secretary pursuant to section 587F of the Federal Food, Drug, and Cosmetic Act. 6. Emergency use authorization (a) In general Section 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3 ) is amended— (1) by inserting or developer after manufacturer , each place such term appears